GLOW vs KLOW: A Research Comparison
Quick Summary
GLOW and KLOW are two of the most-searched skin- and tissue-research blends in the peptide research community. Both stack regenerative tripeptide GHK-Cu with the gastric pentadecapeptide BPC-157 and the actin-binding fragment TB-500. KLOW adds the KPV tripeptide for an additional anti-inflammatory research arm. Researchers compare them to characterize how the KPV addition shifts the inflammatory-modulation profile of the blend.
GLOW
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
KLOW
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
GLOW and KLOW are widely-cited research blends combining several of the most studied regenerative and tissue-research peptides in the literature. Both are designed for in-vitro skin-, dermal-, and connective-tissue research models. The two blends share three components and differ in one — the addition of the tripeptide KPV in KLOW.
GLOW is a three-component research blend: GHK-Cu (the copper-binding tripeptide Gly-His-Lys), BPC-157 (a synthetic pentadecapeptide derived from a gastric-juice protein), and TB-500 (the active C-terminal fragment of Thymosin β4). KLOW retains those three components and adds KPV (Lysine-Proline-Valine), the C-terminal tripeptide of α-MSH widely studied for its anti-inflammatory signaling at MC1R and intracellular IKK pathways.
This page contrasts the two blends across composition, mechanism breadth, primary research applications, and the SKU sizes Pure U.S. Peptides supplies. Researchers select between GLOW and KLOW chiefly based on whether the research design benefits from an additional anti-inflammatory research arm (KPV) layered on top of the regenerative-peptide background.
Side-by-Side: GLOW vs KLOW
| Property | GLOW | KLOW |
|---|---|---|
| Composition | GHK-Cu + BPC-157 + TB-500 | KPV + GHK-Cu + BPC-157 + TB-500 |
| Component count | 3 peptides | 4 peptides |
| Primary mechanism layers | Copper-tripeptide gene modulation, VEGFR2/FAK angiogenesis, actin sequestration | GLOW mechanisms + MC1R / IKK-NF-κB anti-inflammatory signaling |
| Primary research applications | Dermal-repair research, collagen-synthesis assays, hair-follicle models, connective-tissue research | GLOW applications + epithelial-barrier inflammation models, mucosal research, anti-inflammatory dermal research |
| Common research pairings | Glutathione, NAD+, GHK-Cu monotherapy reference | Glutathione, NAD+, KPV-only reference, BPC-157 monotherapy reference |
| SKU sizes available | 50 mg, 75 mg blended vials | 70 mg, 100 mg blended vials |
| Indicative price range | $$ | $$$ |
How the Two Peptides Differ Mechanistically
GLOW combines three complementary mechanisms within a single research blend. GHK-Cu is a copper-binding tripeptide that, in published research, modulates more than 4,000 human genes — chiefly those associated with collagen and decorin synthesis, antioxidant superoxide-dismutase upregulation, and dermal wound-research endpoints.[1] BPC-157 activates VEGFR2 and the FAK-paxillin pathway, with downstream effects on angiogenesis, granulation, and tendon-fibroblast migration in research models.[2][3] TB-500, the active fragment of Thymosin β4, sequesters G-actin and promotes cell migration, with established research interest in dermal and cardiac repair endpoints.[4]
KLOW retains those three pathways and layers in KPV. KPV is the Lysine-Proline-Valine C-terminal tripeptide of α-MSH; published research reports anti-inflammatory signaling chiefly via MC1R activation and inhibition of intracellular IKK/NF-κB activation, with downstream reductions in pro-inflammatory cytokine expression in epithelial-cell research models.[5][6] The KPV arm therefore adds an explicit anti-inflammatory research component on top of the regenerative-peptide background shared with GLOW.
The mechanistic difference between the two blends is the breadth of inflammatory-modulation coverage. GLOW relies on GHK-Cu and BPC-157 for indirect anti-inflammatory effects (cytokine modulation, prostaglandin-pathway interaction). KLOW adds an MC1R-axis component and an additional NF-κB-pathway research lever via KPV.
Research Applications Compared
GLOW is most often referenced in research designs focused on dermal-repair endpoints, collagen-synthesis assays, hair-follicle research models, and connective-tissue research where the combined GHK-Cu / BPC-157 / TB-500 mechanisms map directly onto the experimental endpoints under investigation. The blend is also studied in topical-formulation research and as a reference research tool for multi-mechanism regenerative-peptide work.
KLOW is most often referenced when the research design includes inflammatory-modulation endpoints alongside regenerative endpoints. Examples include epithelial-barrier research models in which KPV-mediated anti-inflammatory signaling is a primary outcome, mucosal-research designs combining gastric-tract (BPC-157) and inflammation-modulation (KPV) endpoints, and dermal-research designs where reduction in pro-inflammatory cytokine expression is tracked alongside collagen and migration endpoints.
Both blends are studied in topical, subcutaneous, and intraperitoneal in-vitro and ex-vivo research formats. Reconstitution and storage research practices follow each component peptide individually — researchers should consult per-peptide chemical-properties pages for stability guidance.
Choosing Between Them
When researchers choose GLOW
GLOW is selected when the research design centers on collagen synthesis, dermal-repair endpoints, angiogenesis assays, or tendon-fibroblast migration models, and when an additional anti-inflammatory research arm is not required. It is the simpler three-peptide blend and the standard regenerative-peptide stack reference.
When researchers choose KLOW
KLOW is selected when the research design pairs regenerative endpoints with inflammatory-modulation endpoints — for example, mucosal-barrier research, epithelial-cytokine assays, or dermal designs that track pro-inflammatory signaling alongside collagen and migration outcomes. The KPV addition layers an MC1R / NF-κB anti-inflammatory research arm on top of the GLOW background.
Chemical Properties Comparison
| Property | GLOW | KLOW |
|---|---|---|
| Molecular Formula | C₁₄H₂₂CuN₆O₄ | C₁₄H₂₂CuN₆O₄ |
| Molecular Weight | ~401.9 Da | ~401.9 Da |
| CAS Number | 89030-95-5 | 89030-95-5 |
| Amino Acid Sequence | — | — |
| PubMed Citations | 24 referenced | 24 referenced |
Explore Full Research Profiles
GLOW
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
KLOW
Overview GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide complex consisting of the amino acids Glycyl-L-Histidyl-L-Lysine chelated to a copper(II) ion. First isolated from human plasma albumin in 1973 by Dr. Loren Pickart at UCSF.[1] Origin: GHK is an endogenous...
Frequently Asked Research Questions
What is the difference in composition between GLOW and KLOW?
+
Why would a researcher choose KLOW over GLOW?
+
Are GLOW and KLOW single peptides?
+
What research applications are most associated with GLOW?
+
What research applications are most associated with KLOW?
+
Can GLOW or KLOW be reconstituted in the same way as the individual peptides?
+
What sizes does Pure U.S. Peptides supply?
+
PubMed Citations Referenced
- [1]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- [2]Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID: 21548867
- [3]Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. PMID: 21030672
- [4]Goldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. PMID: 16099219
- [5]Brzoska T, et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocr Rev. 2008;29(5):581-602. PMID: 18612139
- [6]Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177
- [7]Pickart L, et al. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PMID: 25101282
- [8]Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-9. PMID: 17320857
- [9]Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) research and tissue-repair endpoints. Front Pharmacol. 2018;9:557. PMID: 29910725
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.
Educational Scope. The mechanisms, pathways, and research applications discussed on this page describe published in-vitro, ex-vivo, and animal-model literature. They do not constitute medical advice, recommendations, or guidance for in-human use. Cited PubMed references describe preclinical research findings only. Researchers should consult their institutional review processes and original literature before designing any research study using these compounds.